19 November, 2024
0 Comments
1 category
medicine
Tuesday, November 19, 2024
London – Additional treatment with the PI3K alpha inhibitor inavolisib improved the results of a combination of the CDK4/6 inhibitor palbociclib with the antiestrogen fulvestrant in patients with metastatic hormone receptor (HR)-positive, HER2, in a phase 3 study -negative breast cancer in which previous hormone therapy was no longer effective. Now published in the New England Journal of Medicine (NEJM 2024; DOI:…
#Inavolisib #extends #recurrencefree #life #in..
Category: Medical Encyclopedia
Related Posts
Alzheimer’s antibodies safe in the long term with increasing…
medicine Friday, November 1, 2024 Madrid - Treatment with the…
Lauterbach offers countries a fixed day for hospital reform
Federal Health Minister Karl Lauterbach (SPD) once again defended the…
Robert Koch Institute reports salmonella outbreak, including Germany…
/dpa Berlin – There is an outbreak of certain salmonella…